Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    
    
                         Lexicon Pharmaceuticals, Inc.
                            Selected Financial Data
    
    Consolidated Statements of Operations Data
    (In thousands, except         Three Months Ended       Year Ended
     per share data)                 December 31,          December 31,
                                --------------------  --------------------
                                  2009       2008       2009        2008
                                --------    --------  --------    --------
                                     (unaudited)           (unaudited)
    Revenues:                           
        Collaborative research    $1,292      $4,388    $9,334     $27,177
        Subscription and 
         license fees           
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... GAITHERSBURG, Md. , May 28, 2015  GenVec, ... president and CEO, Douglas J. Swirsky , will ... Healthcare Conference at 11 a.m. EDT on Thursday, June ... webcast of Mr. Swirsky,s presentation will be available at ... also be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce that ... with PTI Inspection Systems. Whitehouse Labs and PTI will ... method development and validation programs using the most ... includes a more formal program that facilitates cross training ... enables a more effective team approach, especially as it ...
(Date:5/28/2015)... Georgia (PRWEB) May 28, 2015 ... National Laboratory (Oak Ridge, TN) recently signed ... of 3D printing plastic resins using nanocellulose, a ... constraint of 3D printing is the limited number ... provide inadequate mechanical strength to printed parts for ...
Breaking Biology Technology:GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 2American Process Inc. Announces Partnership with Oak Ridge National Laboratory to Make 3D Printing Plastic Resins Stronger and More Sustainable 3
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an ... to be launched by,the Company into the China market. ... I tests in July 2006, which consists of tests,for ... tested in,Phases II & III. Aida is currently undergoing ...
... and DETROIT, Oct. 22 The Michigan Life,Science ... rapidly,stimulate new business for Michigan companies. (Photo: ... BioPharma Company, LLC and the Michigan Virtual,Medical Device ... exhibit during,the MichBio Expo convention in Lansing, Michigan. ...
... Highlight and ... of Advanced Practices by Leading, Interventionalists, Broadcast from Around the World. - Hear About ... Stent, Results. - See How Many of the Major Fixed Imaging and Stent Manufacturers ... are Embracing IVUS., ...
Cached Biology Technology:Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 2Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer 3Virtual Life Science Companies Launch and Tour 2Virtual Life Science Companies Launch and Tour 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... contains stem cells with a surprising capacity for repair, ... journal Cell, published by Cell Press. The novel insight ... have clinical implications for the treatment of brain damage, ... mice whose brains were severely damaged by loss of ...
... they have been exposed to biological or chemical weapons could ... who are helping to develop a tiny diagnostic device that ... of a tiny pump, researchers affiliated with MIT's Institute for ... existing miniature "lab on a chip" fully portable, so the ...
... heat-loving archaeon capable of fixing nitrogen at a surprisingly ... Earth’s earliest lineages of organisms capable of nitrogen fixation, ... and animals rely on to fix nitrogen. , ... of Science supports the notion that the gene needed ...
Cached Biology News:Neural stem cells lend the brain a surprising capacity for self-repair 2MIT designs portable 'lab on a chip' 2MIT designs portable 'lab on a chip' 3Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
... ZMD.440. Immunogen: Synthetic peptide derived from ... (platelet derived growth factor D iris-expressed growth ... differs from mouse and rat by one ... the ~50 kDa human mouse and rat ...
...
...
...
Biology Products: